• FDA turns down Ardelyx's chronic kidney disease drug and asks for another trial

    1 month ago - By MedCity News

    Ardelyx drug tenapanor was rejected by the FDA as a treatment for a complication experienced by chronic kidney disease patients. The regulatory decision came two weeks after the company received an FDA letter citing deficiencies in the drug application.
    Read more ...